Gastric cancer is one of the most common cancers in Korea and the world. Since 2004, this
is the 4th gastric cancer guideline published in Korea which is the revised version of …

PURPOSE Adjuvant chemotherapy after D2 gastrectomy is standard for resectable locally
advanced gastric cancer (LAGC) in Asia. Based on positive findings for perioperative …

The synergistic effect of neoadjuvant immunotherapy and chemoradiotherapy in gastric
adenocarcinoma is unclear. This phase II trial (NCT03631615) investigated this neoadjuvant …

Chemotherapy is indispensable for gastric cancer. For unresectable and/or recurrent gastric
cancer, first‐line chemotherapy consists of multidrug regimens including oral 5‐FU agents …

Indocyanine green (ICG) fluorescence imaging-guided lymphadenectomy has been
demonstrated to be effective in increasing the number of lymph nodes (LNs) retrieved in …

Perioperative chemotherapy is the standard treatment for locally advanced gastric or gastro-
esophageal junction cancer, and the addition of programmed cell death 1 (PD-1) inhibitor is …

Oxaliplatin is the main chemotherapy drug for gastric cancer (GC), but quite a few patients
are resistant to oxaliplatin, which contributes to the poor prognosis of GC patients. There is …

Background Adding anti-angiogenics to neoadjuvant chemotherapy for localized gastric
cancer is recognized as a promising strategy, but its clinical value remains to be defined …

Objective A significant proportion of patients can not benefit from neoadjuvant chemotherapy
(NCT) due to drug resistance. Cancer-associated fibroblasts (CAFs) influence many …

Importance The survival benefit of laparoscopic total gastrectomy combined with spleen-
preserving splenic hilar lymphadenectomy (LSTG) for locally advanced proximal gastric …